TransThera Sciences Widens Loss in 2025

MT Newswires Live

03/31

TransThera Sciences (HKG:2617) widened its attributable loss in 2025 to 296 million yuan from 274.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.

The clinical-stage biopharmaceutical firm's loss per share stood at 0.76 yuan in the fiscal year, compared with 0.72 yuan in the previous corresponding year.

The firm did not record any revenue in both periods.

Other income and gains fell 49% to 9.2 million yuan from 17.9 million yuan in the year-ago period, mainly due to a decline in interest income from bank deposits and wealth management products and lower government grants.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2623435585"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2623435585\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2623435585?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-31 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623435585","market":"sg","top_or_hot":-1,"title":"TransThera Sciences Widens Loss in 2025","media":"MT Newswires Live","content":"<html><body><p> TransThera Sciences (HKG:2617) widened its attributable loss in 2025 to 296 million yuan from 274.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.</p><p>The clinical-stage biopharmaceutical firm's loss per share stood at 0.76 yuan in the fiscal year, compared with 0.72 yuan in the previous corresponding year.</p><p>The firm did not record any revenue in both periods.</p><p>Other income and gains fell 49% to 9.2 million yuan from 17.9 million yuan in the year-ago period, mainly due to a decline in interest income from bank deposits and wealth management products and lower government grants.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransThera Sciences Widens Loss in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransThera Sciences Widens Loss in 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-03-31 19:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> TransThera Sciences (HKG:2617) widened its attributable loss in 2025 to 296 million yuan from 274.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.</p><p>The clinical-stage biopharmaceutical firm's loss per share stood at 0.76 yuan in the fiscal year, compared with 0.72 yuan in the previous corresponding year.</p><p>The firm did not record any revenue in both periods.</p><p>Other income and gains fell 49% to 9.2 million yuan from 17.9 million yuan in the year-ago period, mainly due to a decline in interest income from bank deposits and wealth management products and lower government grants.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"藥捷安康-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2623435585","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2623435585","pubTimestamp":1774956404,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TransThera Sciences  widened its attributable loss in 2025 to 296 million yuan from 274.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.The clinical-stage biopharmaceutical firm's loss per share stood at 0.76 yuan in the fiscal year, compared with 0.72 yuan in the previous corresponding year.The firm did not record any revenue in both periods.Other income and gains fell 49% to 9.2 million yuan from 17.9 million yuan in the year-ago period, mainly due to a decline in interest income from bank deposits and wealth management products and lower government grants.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B","BK1161":"生物科技"},"translate_title":"Tranthera Sciences 2025年亏损扩大","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"TransThera Sciences (HKG:2617) widened its attributable loss in 2025 to 296 million yuan from 274.6 million yuan a year prior, according to a Tuesday Hong Kong bourse filing.The clinical-stage biopharmaceutical firm's loss per share stood at 0.76 yuan in the fiscal year, compared with 0.72 yuan in the previous corresponding year.The firm did not record any revenue in both periods.Other income and gains fell 49% to 9.2 million yuan from 17.9 million yuan in the year-ago period, mainly due to a decline in interest income from bank deposits and wealth management products and lower government grants.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}